The drug discovery firm will work with the Dean Felsher Laboratory, using the company’s transomics platform to discover therapies for untreatable cancers.
As previously reported, researchers have determined that ketamine has potential as a treatment for patients at imminent risk for suicide, and as a therapy for treatment-resistant depression.